Higher CD1a Levels Correlate with PD-L1 Expression and Predict Worse Overall Survival in Triple-Negative Breast Carcinoma

Objective: The aim of this study was to measure the expression of PD-L1, CD1a (a marker for immature dendritic cells), and CD83 (a marker for mature dendritic cells) and further examine the associations of PD-L1, CD83, and CD1a with overall survival (OS) in triple-negative breast carcinoma patients. Methods: PD-L1, CD1a, and CD83 expression in breast carcinoma tissues and CD83 expression in lymph node tissues were examined by immunohistochemistry and tissue microarray in 159 patients. Patients were classified into the low, medium, and high PD-L1, CD1a, and CD83 levels. Pearson χ2 test was used to analyze the correlations between PD-L1, CD1a, and CD83. The Kaplan-Meier method was used to calculate the OS. Multivariate analysis was used to identify determinants of 3- and 5-year OS. Results: 25.1, 25.8, and 49.1% of the patients had low, medium, and high PD-L1 levels, respectively. PD-L1 levels significantly correlated with CD1a (r = 0.30409, p < 0.001) and CD83 levels (r = 0.6146, p < 0.001) in breast carcinoma tissue, as well as CD83 levels (r = 0.17508, p = 0.027) in lymph node. The median OS was 83 months (range 12–106), and the 3- and 5-year OS rates were 94.97% (95% CI 91.57–98.37) and 86.79% (95% CI 81.53–92.06), respectively. Moreover, patients with high median CD1a levels had a significantly lower 5-year OS rate (75.6%) than those with low median CD1a levels (93.5%, p = 0.038). Conclusion: PD-L1, CD1a, and CD83 are variably expressed in triple-negative breast carcinoma tissues, and PD-L1 expression correlates with CD1a and CD83. Higher CD1a levels correlate with PD-L1 expression and predict worse OS in triple-negative breast carcinoma.

Download Full-text

Triple Negative Breast Carcinoma: A Comparative Study between Breast Lesion and Lymph Node Metastases: A Preliminary Study

ISRN Pathology ◽

10.5402/2011/598131 ◽

2011 ◽

Vol 2011 ◽

pp. 1-6

Author(s):

David Parada ◽

Karla Peña ◽

Francesc Riu ◽

Pilar Hernandez

Keyword(s):

Lymph Node ◽

Breast Carcinoma ◽

Lymph Node Metastases ◽

Triple Negative ◽

Axillary Lymph ◽

Breast Carcinomas ◽

Variable Expression ◽

Basal Marker ◽

Triple Negative Breast Carcinoma ◽

Node Metastases

Aims and Background. Triple negative breast carcinoma is a genetic and molecular subtype of breast carcinoma with poor prognosis. Some immunohistochemistry studies have been proposed to identify BLBC. Most studies consider primary breast carcinoma but not metastases. Methods. Immunohistochemical characteristics in 11 triple negative breast carcinomas were studied in both primary lesions and lymph node metastases. All cases were reevaluated to estrogen and progesterone receptors and HER2-Neu. An FISH probe for HER2/neu was also performed. Immunohistochemical studies were performed with cytokeratin 5/6, 17, Cam 5.2, p63, EGFR, and Ki-67 in breast carcinoma and lymph node metastases. Results. The age of the patients ranged between 42 and 73 years (mean 53), and the mean followup was 68.25 months. A total of 54.55% of the patients were disease-free, and 45.45% died of carcinoma. Axillary lymph nodes maintained triple negative phenotype (11/11). Metastatic tumors showed CAM 5.2 (81.83%) and EGFR (72.73%) expression. Basal marker expression was variable in primary carcinoma and lymph node metastases (63.64%). Conclusions. Triple negative breast carcinomas maintained this immunoprofile at lymph node metastases. Triple negative carcinomas showed variable expression of basal cell markers.

Download Full-text

In Breast Carcinoma Tissue, Immature Dendritic Cells Reside within the Tumor, Whereas Mature Dendritic Cells Are Located in Peritumoral Areas

Journal of Experimental Medicine ◽

10.1084/jem.190.10.1417 ◽

1999 ◽

Vol 190 (10) ◽

pp. 1417-1426 ◽

Cited By ~ 366

Author(s):

Diana Bell ◽

Pascale Chomarat ◽

Denise Broyles ◽

George Netto ◽

Ghada Moumneh Harb ◽

...

Keyword(s):

Dendritic Cells ◽

Breast Carcinoma ◽

Tumor Cells ◽

Tumor Bed ◽

Carcinoma Tissue ◽

Inflammatory Protein ◽

Immature Dendritic Cells ◽

Cytokeratin Expression ◽

Secondary Lymphoid Organs

We have analyzed the presence of immature and mature dendritic cells (DCs) within adenocarcinoma of the breast using immunohistochemistry. Immature DCs were defined by expression of CD1a-, Langerin-, and intracellular major histocompatibility complex class II–rich vesicles. Mature DCs were defined by expression of CD83 and DC-Lamp. Breast carcinoma cells were defined by morphology and/or cytokeratin expression. We demonstrate two levels of heterogeneity of DCs infiltrating breast carcinoma tissue: (a) immature CD1a+ DCs, mostly of the Langerhans cell type (Langerin+), were retained within the tumor bed in 32/32 samples and (b) mature DCs, CD83+DC-Lamp+, present in 20/32 samples, are confined to peritumoral areas. The high numbers of immature DCs found in the tumor may be best explained by high levels of macrophage inflammatory protein 3α expression by virtually all tumor cells. Confirming the immature/mature DC compartmentalization pattern, in vitro–generated immature DCs adhere to the tumor cells, whereas mature DCs adhere selectively to peritumoral areas. In some cases, T cells are clustering around the mature DCs in peritumoral areas, thus resembling the DC–T cell clusters of secondary lymphoid organs, which are characteristic of ongoing immune reactions.

Download Full-text

Induction of mitochondrial apoptotic pathway in triple negative breast carcinoma cells by methylglyoxal via generation of reactive oxygen species

Molecular Carcinogenesis ◽

10.1002/mc.22665 ◽

2017 ◽

Vol 56 (9) ◽

pp. 2086-2103 ◽

Cited By ~ 10

Author(s):

Anirban Roy ◽

Manisha Ahir ◽

Saurav Bhattacharya ◽

Pravat Kumar Parida ◽

Arghya Adhikary ◽

...

Keyword(s):

Reactive Oxygen Species ◽

Breast Carcinoma ◽

Triple Negative ◽

Reactive Oxygen ◽

Carcinoma Cells ◽

Oxygen Species ◽

Apoptotic Pathway ◽

Mitochondrial Apoptotic Pathway ◽

Breast Carcinoma Cells ◽

Triple Negative Breast Carcinoma

Download Full-text

A STUDY ON THE HISTONE METHYLTRANSFERASE ENHANCER OF ZESTE HOMOLOG 2 EXPRESSION IN BREAST CARCINOMA

10.36106/ijsr/6014009 ◽

2020 ◽

pp. 66-68

Author(s):

Rubaiya Ahmad ◽

Syed Meraj Imam ◽

Debarshi Jana

Keyword(s):

Breast Carcinoma ◽

Breast Tumor ◽

Triple Negative ◽

Histone Methyltransferase ◽

Expression Level ◽

High Grade ◽

Over Expression ◽

Ezh2 Expression ◽

Triple Negative Breast Carcinoma ◽

Enhancer Of Zeste

The over expression of EZH2 in Breast Carcinoma. Compare EZH2 expression in different immunophenotypes of breast carcinoma(basal, luminal, triple-negative). The study EZH2 expression level in association to staging and grading of breast carcinoma Patients attending the Dept of Pathology, Sri Krishna Medical Collage Muzaffarpur, Bihar with epithelial breast tumor. We found that EZH2 in Breast Carcinoma was significantly associated with grade of the tumour. EZH2 was significantly associated with stage of the tumour. It was found that EZH2 was significantly correlated with ki67 in Breast Carcinoma patients. Triple negative Breast Carcinoma patient was significantly associated with high grade of EZH2 tumour.

Download Full-text